Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced the appointment of Christopher Rohde, Ph.D. to the Company's Scientific Advisory Board, effective May 13, 2021.

Dr. Rohde is Co-Founder and Chief Technology Officer at Factor Bioscience. Dr. Rohde is also Co-Founder and President of Novellus Therapeutics. Brooklyn ImmunoTherapeutics acquired an exclusive license for the mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited. Dr. Rohde is currently leading Factor's efforts to apply their RiboSlice™ gene-editing technology, and FactorStem™ cell-reprogramming and differentiation technologies to the development of new research models, including high-throughput screening-compatible human cell libraries. His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many other publications. Chris Rohde earned his Ph.D. from the Massachusetts Institute of Technology (MIT) in 2011.

"As Co-founder and Chief Technology Officer at Factor Bioscience, Dr. Rohde brings a unique and unparalleled understanding of the gene editing and cell therapy technology which Brooklyn has in-licensed to our Scientific Advisory Board," said Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President of Brooklyn. "His in-depth knowledge and perspective will allow us to target disease at the molecular level. This is a very exciting time at Brooklyn and we are looking forward to working with Chris to rapidly advance our potential treatments for oncology, blood disorders and monogenic diseases."

"Brooklyn ImmunoTherapeutics is well-positioned to become a leader in gene editing and cell reprograming using Factor's RiboSlice™ gene-editing technology, and FactorStem™ cell-reprogramming and differentiation technologies," said Dr. Rohde. "I look forward to working with colleagues on the Scientific Advisory Board to optimize this leading edge technology to develop new therapies for patients living with cancer and blood disorders."

About Brooklyn ImmunoTherapeutics
Brooklyn is exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using leading edge gene editing/cell therapy technology through the newly acquired license from Factor Bioscience and Novellus.

For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning Brooklyn's expectations, anticipations, intentions, beliefs or strategies regarding the future that are not statements of historical fact, including statements in the fourth and fifth paragraphs related to potential future development and growth. These statements are based upon the current beliefs and expectations of Brooklyn's management and are subject to significant risks, uncertainties, and other factors. Brooklyn's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors, including, but not limited to: (i) Brooklyn's ability to successfully, cost-effectively and efficiently develop its technology and products; (ii) Brooklyn's ability to successfully commence clinical trials of any products on a timely basis or at all; (iii) Brooklyn's ability to successfully fund and manage the growth of its development activities; (iv) Brooklyn's ability to obtain regulatory approvals of its products for commercialization; and (v) uncertainties related to the impact of the COVID-19 pandemic on the business and financial condition of Brooklyn, including on the timing and cost of the BR-202 clinical trial. Additional factors and risks are described in Brooklyn's periodic reports filed with the Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to Brooklyn on the date of this press release, and Brooklyn assumes no obligation to update the information contained in this press release.